ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia

  • Post author:
  • Post category:Newsroom

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB1) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.